🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

OCEANIC-AF trial: Factor XI inhibitors #revolution in atrial fibrillation is on hold #EHJPharmacotherapy 💊 EHJ-CVP Editor-in-Chief 👨‍💼 European Society of Cardiology European Society of Cardiology Journals 📚 academic.oup.com/ehjcvp/advance… #CardioTwitter #CardioEd #Cardio

#EHJPharmacotherapy 💊

Old truth may be true; Inotropes may increase mortality in patients with cardiogenic shock.

News from #EHJPharmacotherapy 🔥

An aspirin-free strategy for #PCI in patients with #diabetes: new data from the STOPDAPT-3 trial just published in #EHJPharmacotherapy 💊 bit.ly/48uCzXo Masahiro Natsuaki Hirotoshi Watanabe Felice Gragnano Mattia Galli European Society of Cardiology Journals

#EHJPharmacotherapy Editor’s Choice 🫀 #Effectiveness and #safety of direct oral anticoagulation vs. warfarin in #frail patients with atrial fibrillation academic.oup.com/ehjcvp/article… EHJ-CVP Editor-in-Chief Stefan Agewall Felice Gragnano European Society of Cardiology Journals #CardioTwitter #CardioEd #escardio

Our invited commentary published in the new Dec issue of the #EHJCVP. 🙏 Stefan Agewall for the invitation & Professor Peter Penson 💊🫀 for joint work on this! We will use any occasion to promote SPC as the best way to have our patients on goal and reduce CVD burden. academic.oup.com/ehjcvp/article…

Find out more from the new TITIAN study in #EHJPharmacotherapy: a pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction 👉 bit.ly/40uClgB EHJ-CVP Editor-in-Chief Felice Gragnano Davide Capodanno Claudio Laudani

BMI is important

Can we use DOAC in frail patients?

📢 Fresh off the press in #EHJPharmacotherapy! The EMPAG-HF trial unveils the acute effects of #empagliflozin on left atrial and ventricular filling parameters using echocardiography in patients with #HF 💊🩺 Read more: ow.ly/apkc50Va7LG EHJ-CVP Editor-in-Chief Felice Gragnano

Is triple therapy with statin, ezetimibe and bempedoic acid an option? Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia Felice Gragnano EHJ-CVP Editor-in-Chief Nikos Pyrpyris academic.oup.com/ehjcvp/article…

The EMPAG-HF trial unveils the acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography in patients with HF

Triple lipid lowering drugs

#Colchicine in STEMI: #CLEAR results, #cloudy impact What do the conflicting results tell us❓ Do we need further studies❓ Is there an optimal patient #phenotype❓ 📍More at #EHJPharmacotherapy ➡️ academic.oup.com/ehjcvp/advance… #CardioX #Cardiology #Heart EHJ-CVP Editor-in-Chief European Society of Cardiology Journals

We have more than statins to use in the lipid therapy

Apixaban outcomes in AF patients with single dose-reduction criterion

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy

Is albumin level associated with risk of major bleeding in patients with Afib on DOACs?

🧠💊 Is clopidogrel a *smart choice* for long-term antiplatelet monotherapy in patients with coronary artery disease? We share our perspective in our latest article in #EHJPharmacotherapy! 📖🔍 👉 academic.oup.com/ehjcvp/advance… Paolo Calabro' Vincenzo De Sio Mattia Galli EHJ-CVP Editor-in-Chief